Ampio Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mike Martino

Chief Executive Officer (CEO)

US$668.1k

Compensación total

Porcentaje del salario del CEO	82.0%
Permanencia del CEO	2.1yrs
Participación del CEO	0.5%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Martino en comparación con los beneficios de Ampio Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$668k	US$548k	-US$16m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$60k	-US$17m

Compensación vs. Mercado: La compensación total de Mike($USD668.14K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD476.59K).

Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.

CEO

Mike Martino (66 yo)

2.1yrs

Permanencia

US$668,141

Compensación

Mr. Michael A. Martino, also known as Mike, has served as Chairman of the Board of Directors at Ampio Pharmaceuticals, Inc. since November 2021 until November 22, 2022 and served as its Interim Chairman of...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Martino	CEO & Director	2.2yrs	US$668.14k	0.46% € 6.8k
David Bar-Or	Founder & Chairman of Scientific Advisory Board	3yrs	US$145.60k	sin datos
J. Buchi	Independent Chairman	2.2yrs	US$99.71k	0.88% € 13.0k
David Stevens	Independent Director	12.5yrs	US$65.54k	0.62% € 9.2k
Elizabeth Jobes	Independent Director	1.8yrs	US$108.91k	0% € 0

2.2yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de APH no se considera experimentada (2.2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Ampio Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad